Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.69 |
| ▸ | GABRA1 | P14867 | 5/20 | 0.36 |
| ▸ | GABRA2 | P47869 | 5/20 | 0.36 |
| ▸ | PRLHR | P49683 | 4/20 | 0.33 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.31 |
| ▸ | TPH1 | P17752 | 1/20 | 0.31 |
| ▸ | DRD4 | P21917 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.31 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2381699 | 1.00 | NR1H4 (0.69) | NR1H4GABRA1GABRA2PRLHRP2RX3 | |
| SCHEMBL2382373 | 0.98 | NR1H4 (0.67) | NR1H4GABRA1GABRA2PRLHRPTGDR2 | |
| SCHEMBL1712425 | 0.85 | NR1H4 (0.50) | NR1H4PTGDR2HTR2AHTR2CSLC6A4 | |
| SCHEMBL1712306 | 0.84 | NR1H4 (0.49) | NR1H4GABRA1GABRA2PTGDR2HTR2A | |
| SCHEMBL1724253 | 0.82 | NR1H4 (0.77) | NR1H4GABRA1GABRA2 | |
| SCHEMBL2383060 | 0.82 | NR1H4 (0.77) | NR1H4GABRA1GABRA2 | |
| SCHEMBL12012950 | 0.80 | NR1H4 (0.74) | NR1H4GABRA1GABRA2 | |
| SCHEMBL2382062 | 0.80 | NR1H4 (0.97) | NR1H4GABRA1GABRA2MDM2 | |
| SCHEMBL12394134 | 0.77 | NR1H4 (0.46) | NR1H4GABRA1GABRA2CYP19A1 | |
| SCHEMBL1712092 | 0.76 | NR1H4 (0.44) | NR1H4PRLHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2344459-B1 | 2,3-SUBSTITUTED INDAZOLE OR 4,5,6,7-TETRAHYDRO-INDAZOLES AS FXR MODULATORS AGAINST DYSLIPIDEMIA AND RELATED DISEASES | HOFFMANN LA ROCHE (CH) | 2013-12-25 | — | — | EP | claimed |
| US-8008505-B2 | Indazole or 4,5,6,7-tetrahydro-indazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-08-30 | — | — | US | claimed |
| EP-2344459-A1 | 2,3-SUBSTITUTED INDAZOLE OR 4,5,6,7-TETRAHYDRO-INDAZOLES AS FXR MODULATORS AGAINST DYSLIPIDEMIA AND RELATED DISEASES | F. Hoffmann-La Roche AG (CH) | 2011-07-20 | — | — | EP | claimed |
| WO-2010034649-A1 | 2,3-SUBSTITUTED INDAZOLE OR 4,5,6,7-TETRAHYDRO-INDAZOLES AS FXR MODULATORS AGAINST DYSLIPIDEMIA AND RELATED DISEASES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-04-01 | — | — | WO | claimed |
| US-20100076027-A1 | INDAZOLE OR 4,5,6,7-TETRAHYDRO-INDAZOLE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2010-03-25 | — | — | US | claimed |
| EP-2344459-B1 | 2,3-SUBSTITUTED INDAZOLE OR 4,5,6,7-TETRAHYDRO-INDAZOLES AS FXR MODULATORS AGAINST DYSLIPIDEMIA AND RELATED DISEASES | HOFFMANN LA ROCHE (CH) | 2013-12-25 | — | — | EP | disclosed |
| US-8008505-B2 | Indazole or 4,5,6,7-tetrahydro-indazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-08-30 | — | — | US | disclosed |
| US-8008505-B2 | Indazole or 4,5,6,7-tetrahydro-indazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-08-30 | — | — | US | disclosed |
| EP-2344459-A1 | 2,3-SUBSTITUTED INDAZOLE OR 4,5,6,7-TETRAHYDRO-INDAZOLES AS FXR MODULATORS AGAINST DYSLIPIDEMIA AND RELATED DISEASES | F. Hoffmann-La Roche AG (CH) | 2011-07-20 | — | — | EP | disclosed |
| WO-2010034649-A1 | 2,3-SUBSTITUTED INDAZOLE OR 4,5,6,7-TETRAHYDRO-INDAZOLES AS FXR MODULATORS AGAINST DYSLIPIDEMIA AND RELATED DISEASES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-04-01 | — | — | WO | disclosed |
| WO-2010034649-A1 | 2,3-SUBSTITUTED INDAZOLE OR 4,5,6,7-TETRAHYDRO-INDAZOLES AS FXR MODULATORS AGAINST DYSLIPIDEMIA AND RELATED DISEASES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-04-01 | — | — | WO | disclosed |
| US-20100076027-A1 | INDAZOLE OR 4,5,6,7-TETRAHYDRO-INDAZOLE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2010-03-25 | — | — | US | disclosed |
| US-20100076027-A1 | INDAZOLE OR 4,5,6,7-TETRAHYDRO-INDAZOLE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076027-A1 | INDAZOLE OR 4,5,6,7-TETRAHYDRO-INDAZOLE DERIVATIVES | NR1H4, ABCB11, FXR1 | NR1H4 1/4885GABRA1 915/4885GABRA2 1203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.